Jasper Therapeutics' 15min chart shows MACD Death Cross, KDJ Death Cross.

According to the 15-minute chart for Jasper Therapeutics, the MACD Death Cross and KDJ Death Cross were triggered on July 14, 2025 at 09:45. This indicates that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and is likely to further decrease.

Jasper Therapeutics (JSPR) saw a significant drop in its stock price on July 14, 2025, after the company announced a series of strategic measures aimed at extending its cash runway. The stock fell by 5.6% to $2.85, following the news that the company is reducing its workforce by 50% and halting most of its clinical and preclinical programs [1].

The company stated that it is focusing its resources on the experimental drug Briquilimab, which is being tested as a treatment for chronic urticaria, a condition characterized by persistent hives. The drug works by targeting specific immune cells involved in causing the hives and inflammation. Dr. Edwin Tucker, the current Chief Medical Officer, is stepping down, and Dr. Daniel Adelman will take over as the Acting Chief Medical Officer [1].

Analysts from H.C. Wainwright have lowered their price target on Jasper Therapeutics to $20 from $40, citing delays in key programs and recent cost-cutting measures. Despite the efforts to reduce expenses, the firm believes Jasper will likely need to raise additional capital around Q4 2025 to support ongoing operations [2].

The company’s shares plummeted over 50% intra-day on July 14, 2025, after it announced the halt of its asthma study and other programs. The analysts noted that this decision will reduce operating expenses by an estimated 25% starting in Q3 2025 compared to Q2 levels [2].

Jasper Therapeutics has seen a significant reduction in its stock price year-to-date, with a decrease of 86.2% as of the last close. The company is focusing its efforts on Briquilimab for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), with potential data releases expected later this year [3].

References:
[1] Reuters. (2025). Jasper Therapeutics Falls After Halting Clinical Programs. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L6N3T60LY:0-jasper-therapeutics-falls-after-halting-clinical-programs/
[2] FinancialModelingPrep. (2025). H.C. Wainwright Cuts Jasper Therapeutics Price Target Following Asthma Study Halt. Retrieved from https://site.financialmodelingprep.com/market-news/fmp-hc-wainwright-cuts-jasper-therapeutics-price-target-following-asthma-study-halt
[3] Nasdaq. (2025). Jasper Therapeutics Announces 50% Workforce Reduction and Leadership Change. Retrieved from https://www.nasdaq.com/articles/jasper-therapeutics-announces-50-workforce-reduction-and-leadership-change-enhance-focus